BAUSCH HEALTH COS INC (BHC) Fundamental Analysis & Valuation
NYSE:BHC • CA0717341071
5.04 USD
-0.39 (-7.18%)
Last: Mar 12, 2026, 03:18 PM
This BHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
BHC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of BHC while its profitability can be described as average. BHC is cheap, but on the other hand it scores bad on growth.
1. BHC Profitability Analysis
1.1 Basic Checks
- BHC had positive earnings in the past year.
- BHC had a positive operating cash flow in the past year.
- BHC had negative earnings in 4 of the past 5 years.
- Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
- BHC has a better Return On Assets (0.60%) than 79.79% of its industry peers.
- The Return On Invested Capital of BHC (7.78%) is better than 87.05% of its industry peers.
- BHC had an Average Return On Invested Capital over the past 3 years of 6.89%. This is significantly below the industry average of 13.09%.
- The 3 year average ROIC (6.89%) for BHC is below the current ROIC(7.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- BHC has a better Profit Margin (1.53%) than 79.79% of its industry peers.
- The Operating Margin of BHC (21.28%) is better than 88.60% of its industry peers.
- In the last couple of years the Operating Margin of BHC has grown nicely.
- BHC has a Gross Margin of 70.65%. This is in the better half of the industry: BHC outperforms 77.72% of its industry peers.
- In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. BHC Health Analysis
2.1 Basic Checks
- BHC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, BHC has more shares outstanding
- The number of shares outstanding for BHC has been increased compared to 5 years ago.
- The debt/assets ratio for BHC has been reduced compared to a year ago.
2.2 Solvency
- BHC has an Altman-Z score of 0.28. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of 0.28, BHC perfoms like the industry average, outperforming 51.30% of the companies in the same industry.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- BHC has a Debt to FCF ratio of 21.00. This is in the better half of the industry: BHC outperforms 75.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.28 |
ROIC/WACC1.2
WACC6.51%
2.3 Liquidity
- BHC has a Current Ratio of 1.47. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- BHC has a Current ratio of 1.47. This is in the lower half of the industry: BHC underperforms 70.47% of its industry peers.
- BHC has a Quick Ratio of 1.08. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- BHC's Quick ratio of 1.08 is on the low side compared to the rest of the industry. BHC is outperformed by 75.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. BHC Growth Analysis
3.1 Past
- The earnings per share for BHC have decreased by 0.00% in the last year.
- Measured over the past years, BHC shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.13% on average per year.
- Looking at the last year, BHC shows a small growth in Revenue. The Revenue has grown by 6.66% in the last year.
- The Revenue has been growing slightly by 5.04% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- The Earnings Per Share is expected to decrease by -1.34% on average over the next years.
- Based on estimates for the next years, BHC will show a decrease in Revenue. The Revenue will decrease by -0.94% on average per year.
EPS Next Y15.65%
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue Next Year4.35%
Revenue Next 2Y2.09%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. BHC Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 1.34, which indicates a rather cheap valuation of BHC.
- BHC's Price/Earnings ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
- BHC is valuated cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
- BHC is valuated cheaply with a Price/Forward Earnings ratio of 1.16.
- Based on the Price/Forward Earnings ratio, BHC is valued cheaper than 98.96% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.27. BHC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.34 | ||
| Fwd PE | 1.16 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 94.30% of the companies listed in the same industry.
- BHC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.88 | ||
| EV/EBITDA | 6.35 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BHC has a very decent profitability rating, which may justify a higher PE ratio.
- BHC's earnings are expected to decrease with -5.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
5. BHC Dividend Analysis
5.1 Amount
- No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BHC Fundamentals: All Metrics, Ratios and Statistics
NYSE:BHC (3/12/2026, 3:18:05 PM)
5.04
-0.39 (-7.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-28 2026-04-28
Inst Owners44.72%
Inst Owner Change-1.85%
Ins Owners11.42%
Ins Owner Change10.17%
Market Cap1.87B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.43 (47.42%)
Short Float %1.72%
Short Ratio2.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)-0.23%
PT rev (3m)1.85%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)0.22%
EPS NY rev (1m)1.65%
EPS NY rev (3m)1.71%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.34 | ||
| Fwd PE | 1.16 | ||
| P/S | 0.18 | ||
| P/FCF | 1.88 | ||
| P/OCF | 1.33 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.35 |
EPS(TTM)3.77
EY74.8%
EPS(NY)4.36
Fwd EY86.51%
FCF(TTM)2.68
FCFY53.17%
OCF(TTM)3.78
OCFY74.96%
SpS27.7
BVpS-1.5
TBVpS-44.44
PEG (NY)0.09
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.28 |
F-Score6
WACC6.51%
ROIC/WACC1.2
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y15.65%
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.35%
Revenue Next 2Y2.09%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.11%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
Can you provide the valuation status for BAUSCH HEALTH COS INC?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.